Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.83 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.83 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.83 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.83 |
| ▸ | MAPT | P10636 | 5/20 | 0.83 |
| ▸ | XDH | P47989 | 5/20 | 0.83 |
| ▸ | APP | P05067 | 5/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.83 |
| ▸ | BCHE | P06276 | 4/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.83 |
| ▸ | ACHE | P22303 | 4/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974792 | 1.00 | MEN1 (0.83) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Myricetin SCHEMBL29357150 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Myricetin SCHEMBL3503992 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Myricetin SCHEMBL19302 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21565057 | 0.89 | MEN1 (0.65) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28432225 | 0.86 | MEN1 (0.85) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7929171 | 0.84 | MEN1 (0.81) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Myricetin SCHEMBL15609358 | 0.84 | MEN1 (0.89) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15197351 | 0.84 | MEN1 (0.81) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Myricetin SCHEMBL1064954 | 0.83 | MEN1 (0.92) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165831-A1 | METHOD AND COMPOSITION FOR RENDERING CANCER CELLS SUSCEPTIBLE TO TREATMENT BY TARGETED ONCOGENETIC DRIVERS | IMPACT BIOLIFE SCIENCE, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165831-A1 | METHOD AND COMPOSITION FOR RENDERING CANCER CELLS SUSCEPTIBLE TO TREATMENT BY TARGETED ONCOGENETIC DRIVERS | IMPACT BIOLIFE SCIENCE, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230132782-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132782-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4121040-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | Global Biolife Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115397410-A | Methods and compositions for treating, preventing, or limiting the occurrence of viral infections | 环球生物生命有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021188520-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10966954-B2 | Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders | GLOBAL BIOLIFE INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020150146-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIAC INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20190343792-A1 | ELECTROPHILICALLY ENHANCED PHENOLIC COMPOUNDS FOR TREATING INFLAMMATORY RELATED DISEASES AND DISORDERS | GLOBAL BIOLIFE INC. | 2019-11-14 | — | — | US | disclosed |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | STEM CELL THERANOSTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20140221183-A1 | CHARGING MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2014-08-07 | — | — | US | disclosed |
| WO-2010033847-A1 | NGAL-BINDING SIDEROPHORES AND USE THEREOF TO TREAT IRON DEFICIENCY AND IRON OVERLOAD | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132782-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | ACE2, ACE, TMPRSS2 | MEN1 3344/4885KMT2A 4009/4885CYP1A2 106/4885 |
| US-10966954-B2 | Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders | HRH2, HRH3, HRH4 | MEN1 4881/4885KMT2A 2818/4885CYP1A2 68/4885 |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | RDX, TNNT2, CHLSN | MEN1 1453/4885KMT2A 1476/4885CYP1A2 300/4885 |
| US-20230165831-A1 | METHOD AND COMPOSITION FOR RENDERING CANCER CELLS SUSCEPTIBLE TO TREATMENT BY TARGETED ONCOGENETIC DRIVERS | KRAS, NRAS, TP53 | MEN1 340/4885KMT2A 673/4885CYP1A2 2428/4885 |
| US-20190343792-A1 | ELECTROPHILICALLY ENHANCED PHENOLIC COMPOUNDS FOR TREATING INFLAMMATORY RELATED DISEASES AND DISORDERS | HRH2, HRH3, HRH4 | MEN1 4881/4885KMT2A 2818/4885CYP1A2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.